Abstract
Neoadjuvant therapy (NAT) is the recommended approach to early HER2+ breast cancer (BC). Anthracycline (ANTR)-polychemotherapy (CT) regimens have been the first choice but newer combinations with multiple anti-HER2 agents with or without ANTR have also shown efficacy. The questions of the optimal combination and whether ANTR could be omitted remain.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
